EVT0185

Overview

EVT0185 is an orally active ATP citrate lyase ( ACLY ) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC 50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer , such as hepatocellular carcinoma (HCC).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > ATP Citrate Lyase

Product Information

• Catalog No.: HY-175606
• CAS No.: 2588489-03-4
• Molecular Formula: C22H34O4
• Molecular Weight: 362.50
• Purity: 99.39%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (6.90 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source